Syntekabio Posts ₩1.2 Billion Revenue in First Half of the Year

Syntekabio (Ticker: 226330) announced on the 14th that it recorded cumulative revenue of ₩1.2 billion for the first half of this year, including ₩300 million in the second quarter.

By exceeding the listing maintenance requirements — ₩700 million half‑yearly and ₩300 million quarterly — the company has put market concerns to rest. The launch of its data center leasing (IDC) business and a newly established system integration (SI) division added further growth momentum to drive its half‑year performance.

Among the first‑half revenue, over ₩1.0 billion was generated by its AI drug discovery platform, DeepMatcher. A Syntekabio spokesperson noted, “This shows DeepMatcher is not only achieving research milestones, but also generating direct revenue,” underscoring the platform’s real competitive edge and market viability.

The remaining revenue came from its eco‑friendly data center IDC leasing business and the newly launched SI services in Q2. Through the SI division, it secured its first contract — an eCommerce development project worth approximately ₩100 million. In Q3, the company continues to win contracts including for eCommerce site builds, website development, and large‑scale data preprocessing, delivering consistent business results. The company expects significant contracts in the data center business in Q4.

Syntekabio plans to make these two areas — the data center and SI services — key pillars for diversified revenue generation. “Our AI drug discovery platform business has become the core focus of revenue, while we are diversifying through the data center and new SI business,” said a company representative. “We expect to maintain stable revenue flow and deliver new business results in the second half of the year.”

Source: eDaily (Article from Edaily News)

Original Link: https://www.edaily.co.kr/News/Read?newsId=05100406642267320&mediaCodeNo=257&OutLnkChk=Y